CD44 and hepatocellular carcinoma: HCC-derived CD44+ organoids displayed sorafenib-resistance, and a GLI inhibitor, GANT61, suppressed proliferation of both CD44+-HCC patient-derived organoids and CD44+ hepatoma cells, indicating that CD44+ cells with a sorafenib-resistant phenotype was maintained by the Hh signaling [69].